ClinicalTrials.gg
RecruitingNCT05363280Updated May 8, 2026

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

A Phase 2 interventional study of AL8326 40 mg and AL8326 60 mg in Small Cell Lung Cancer, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung, sponsored by Advenchen Pharmaceuticals, LLC.. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Advenchen Pharmaceuticals, LLC. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 630 studies in Small Cell Lung Carcinoma with a site in United States — 111 open to participants now, 182 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.

Planned enrollment
215th of 551
80 · median 55
Started
2022
with 25 others
Phase 2
186 of 630
24 open now
Primary completion
2027-12
later than 85 of 181 live
Registered
496th of 630
by date

Among the 630 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 215th largest by planned enrollment of the 551 interventional ones that give a count, is one of 26 that started in 2022, is one of 186 in phase 2, reaches primary completion later than 85 of the 181 other live ones, and was the 496th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

111 of the 630 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 630 studies in Small Cell Lung Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma patients who need ≥2nd line treatment .

Read the detailed description

This study is designed for two steps: Phase 2 Optimal Biological Dose (OBD) finding and Phase 2 expansion cohort study after OBD determination.

The Phase 2 study aims to find optimal biological dose (OBD) initially. Patients will be randomized to 3 different dosing groups in OBD finding cohorts. Each cohort will enroll 6-12 SCLC patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. This OBD finding cohort will also evaluate the pharmacokinetic profile of AL8326.

OBD patient enrollment of 40 mg (n=12) and 60 mg (N=12) have been completed, waiting data maturing, 80 mg (n=4) has been stopped due to high intolerability. 40mg and 60mg cohort group can be expanded to an additional 6-12 patients in each cohort with only sparse PK sampling requirement if OBD is not able to be determined in early 12 patients of each cohort. Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma (RCC) are added to this protocol as additional expansion cohorts.

03

Conditions studied

  • Small Cell Lung Cancer
  • Renal Cell Carcinoma (RCC)
  • Non-Small Cell Lung

Keywords

  • Recurrent small cell lung caner
  • Advanced small cell lung cancer
  • Metastatic Small lung cancer
  • ≥2nd Line treatment
  • Non small cell lung cancer
  • Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  1. Male or female, 18 years of age or older
  2. performance status of 0 or 1
  3. or cytologically confirmed SCLC /NSCLC/RCC
  4. Have at least 1 lesion that meets the criteria for being measurable, as defined by 1.1
  5. Have a of at least 3 months

Major Exclusion Criteria:

  1. Serious, non-healing wound, ulcer or bone fracture
  2. Major surgical procedure within 28 days or minor surgical procedure performed within 7 days prior to treatment
  3. Active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
  4. cardiovascular disease including uncontrolled hypertension; myocardial infarction or unstable angina within 6 months prior to enrollment; (NYHA) Grade II or greater congestive heart failure serious cardiac arrhythmia requiring medication; and Grade II or greater peripheral vascular disease
  5. Hemoptysis within 3 months prior to enrollment
  6. Concomitant treatment with strong inhibitors or inducers of , CYP2C9 and CYP2C19 within 14 days prior to enrollment and during the study unless there is an emergent or life-threatening medical condition that required it.

More information available upon request

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    OBD finding cohort at low dose--completed

    Subject in low dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.

    Drug: AL8326 40 mg

  • Experimental
    OBD finding cohort at middle dose--completed

    Subject in middle dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.

    Drug: AL8326 60 mg

  • Experimental
    OBD finding cohort at high dose--completed

    Subject in high dose group will receive AL8326 orally in each cycle until intolerable toxicity or disease progression or withdrawal . 6-12 subjects are in this group. Efficacy, safety and PK will be evaluated and compared within 3 different dosing group to define the final OBD.

    Drug: AL8326 80 mg--stopped

  • Experimental
    Non-Small Cell Lung(NSCLC)

    ≥2nd line NSCLC patient in 40 mg dose

    Drug: AL8326 40 mg

  • Experimental
    Renal Cell Carcinoma( RCC )

    ≥2nd line RCC patient in 60 mg dose

    Drug: AL8326 60 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Optimal biological dose ( OBD )

    Determine the Optimal biological dose ( OBD ) via evaluation of dose limiting toxicity (DLT) events to decide the dosing using in expanded cohort

    Time frame: 12 months

  2. Objective Response Rates (ORR)

    Evaluate the efficacy among 3 different dosing groups

    Time frame: 12 month

  3. ORR evaluation for NSCLC and RCC

    ORR evaluation for NSCLC and RCC

    Time frame: 24 month

Secondary outcomes

  1. Duration of response ( DOR)

    DOR for SCLC OBD group plus expansion cohort, NSCLC and RCC cohortgroup;

    Time frame: 36 month

  2. Progression-Free Survival (PFS)

    PFS for SCLC OBD group plus expansion cohort, NSCLC and RCC cohortgroup

    Time frame: 36 month

  3. Pharmacokinetic endpoints

    Pharmacokinetic endpoints Maximum Plasma Concentration ( Cmax)

    Time frame: 24 month

  4. Pharmacokinetic endpoint Area Under the Curve (AUC)

    Time frame: 24 month

07

Study locations

5 of 7 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Dec 2027, 61 months after the start.

Of 54 industry-sponsored phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 44. This study's planned 61 months is above that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2022
First posted
May 5, 2022
StartActual
Nov 1, 2022
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05363280
Lead sponsor
Advenchen Pharmaceuticals, LLC.
Responsible party
Sponsor
First posted
May 5, 2022
Start date
Nov 1, 2022
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 8, 2026

Study contacts

Shiying Sprinzl
Contact
shiyings@advenchen.com
805-530-1550
Judy Chen
Contact
Judyc@advenchen.com
805-530-1550
Saiama Waqar, MD
principal investigator · Washington University School of Medicine

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aurora B/VEGFR/FGFR Inhibitor AL8326

Start the discussion